JP2010536739A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010536739A5 JP2010536739A5 JP2010520640A JP2010520640A JP2010536739A5 JP 2010536739 A5 JP2010536739 A5 JP 2010536739A5 JP 2010520640 A JP2010520640 A JP 2010520640A JP 2010520640 A JP2010520640 A JP 2010520640A JP 2010536739 A5 JP2010536739 A5 JP 2010536739A5
- Authority
- JP
- Japan
- Prior art keywords
- polymer
- motif
- uracil
- cytosine
- outside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000642 polymer Polymers 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 10
- 230000003308 immunostimulating effect Effects 0.000 claims 9
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Natural products O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 8
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Natural products NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 7
- 229940035893 uracil Drugs 0.000 claims 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 6
- 150000004713 phosphodiesters Chemical group 0.000 claims 6
- 229940104302 cytosine Drugs 0.000 claims 5
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 5
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 claims 4
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 claims 4
- PNWOYKVCNDZOLS-UHFFFAOYSA-N 6-amino-5-chloro-1h-pyrimidin-2-one Chemical compound NC=1NC(=O)N=CC=1Cl PNWOYKVCNDZOLS-UHFFFAOYSA-N 0.000 claims 4
- RGKBRPAAQSHTED-UHFFFAOYSA-N 8-oxoadenine Chemical compound NC1=NC=NC2=C1NC(=O)N2 RGKBRPAAQSHTED-UHFFFAOYSA-N 0.000 claims 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical group O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims 4
- -1 nosome Substances 0.000 claims 4
- 150000003212 purines Chemical class 0.000 claims 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 4
- 102000006992 Interferon-alpha Human genes 0.000 claims 3
- 108010047761 Interferon-alpha Proteins 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000000087 stabilizing effect Effects 0.000 claims 3
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 claims 2
- GIIGHSIIKVOWKZ-UHFFFAOYSA-N 2h-triazolo[4,5-d]pyrimidine Chemical compound N1=CN=CC2=NNN=C21 GIIGHSIIKVOWKZ-UHFFFAOYSA-N 0.000 claims 2
- BISHACNKZIBDFM-UHFFFAOYSA-N 5-amino-1h-pyrimidine-2,4-dione Chemical compound NC1=CNC(=O)NC1=O BISHACNKZIBDFM-UHFFFAOYSA-N 0.000 claims 2
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 claims 2
- ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 claims 2
- JDBGXEHEIRGOBU-UHFFFAOYSA-N 5-hydroxymethyluracil Chemical compound OCC1=CNC(=O)NC1=O JDBGXEHEIRGOBU-UHFFFAOYSA-N 0.000 claims 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 2
- QFVKLKDEXOWFSL-UHFFFAOYSA-N 6-amino-5-bromo-1h-pyrimidin-2-one Chemical compound NC=1NC(=O)N=CC=1Br QFVKLKDEXOWFSL-UHFFFAOYSA-N 0.000 claims 2
- NLLCDONDZDHLCI-UHFFFAOYSA-N 6-amino-5-hydroxy-1h-pyrimidin-2-one Chemical compound NC=1NC(=O)N=CC=1O NLLCDONDZDHLCI-UHFFFAOYSA-N 0.000 claims 2
- CLGFIVUFZRGQRP-UHFFFAOYSA-N 7,8-dihydro-8-oxoguanine Chemical class O=C1NC(N)=NC2=C1NC(=O)N2 CLGFIVUFZRGQRP-UHFFFAOYSA-N 0.000 claims 2
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims 2
- 229930010555 Inosine Natural products 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 2
- 108010065805 Interleukin-12 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 2
- 108091028664 Ribonucleotide Proteins 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000005547 deoxyribonucleotide Substances 0.000 claims 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims 2
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims 2
- 229960004413 flucytosine Drugs 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 239000001257 hydrogen Chemical class 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 229960003786 inosine Drugs 0.000 claims 2
- 229940117681 interleukin-12 Drugs 0.000 claims 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 2
- PSHHQIGKVLIVBD-UHFFFAOYSA-N purine-2,4-diamine Chemical compound C1=NC(N)=NC2(N)N=CN=C21 PSHHQIGKVLIVBD-UHFFFAOYSA-N 0.000 claims 2
- 239000002336 ribonucleotide Substances 0.000 claims 2
- 125000002652 ribonucleotide group Chemical group 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical class N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 claims 1
- RYYIULNRIVUMTQ-UHFFFAOYSA-N 6-chloroguanine Chemical class NC1=NC(Cl)=C2N=CNC2=N1 RYYIULNRIVUMTQ-UHFFFAOYSA-N 0.000 claims 1
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 claims 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 claims 1
- 229960005508 8-azaguanine Drugs 0.000 claims 1
- 208000035657 Abasia Diseases 0.000 claims 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 229940124614 TLR 8 agonist Drugs 0.000 claims 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 1
- 239000000412 dendrimer Substances 0.000 claims 1
- 229920000736 dendritic polymer Polymers 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 239000002479 lipoplex Substances 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000000693 micelle Substances 0.000 claims 1
- 239000004530 micro-emulsion Substances 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 239000007908 nanoemulsion Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 229960003087 tioguanine Drugs 0.000 claims 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims 1
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 239000000277 virosome Substances 0.000 claims 1
- 239000007762 w/o emulsion Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96444807P | 2007-08-13 | 2007-08-13 | |
| US60/964,448 | 2007-08-13 | ||
| PCT/IB2008/002104 WO2009022216A2 (en) | 2007-08-13 | 2008-08-08 | Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010536739A JP2010536739A (ja) | 2010-12-02 |
| JP2010536739A5 true JP2010536739A5 (enExample) | 2011-01-20 |
| JP4847609B2 JP4847609B2 (ja) | 2011-12-28 |
Family
ID=40351228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010520640A Active JP4847609B2 (ja) | 2007-08-13 | 2008-08-08 | 特異的な免疫修飾プロフィールを誘発する規定されたヌクレオチド間結合との関連におけるｒｎａ配列モチーフ |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US8128944B2 (enExample) |
| EP (1) | EP2179039B1 (enExample) |
| JP (1) | JP4847609B2 (enExample) |
| KR (1) | KR20100045508A (enExample) |
| CN (1) | CN101821392B (enExample) |
| AR (1) | AR067928A1 (enExample) |
| AU (1) | AU2008288241B2 (enExample) |
| BR (1) | BRPI0814260B8 (enExample) |
| CA (1) | CA2696630C (enExample) |
| CL (1) | CL2008002371A1 (enExample) |
| CO (1) | CO6260153A2 (enExample) |
| DK (1) | DK2179039T3 (enExample) |
| ES (1) | ES2703876T3 (enExample) |
| MX (1) | MX2010001014A (enExample) |
| NZ (1) | NZ582972A (enExample) |
| PL (1) | PL2179039T3 (enExample) |
| PT (1) | PT2179039T (enExample) |
| RU (1) | RU2435851C2 (enExample) |
| SI (1) | SI2179039T1 (enExample) |
| TR (1) | TR201820474T4 (enExample) |
| TW (1) | TW200916106A (enExample) |
| WO (1) | WO2009022216A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4847609B2 (ja) | 2007-08-13 | 2011-12-28 | コーリー ファーマシューティカル ゲーエムベーハー | 特異的な免疫修飾プロフィールを誘発する規定されたヌクレオチド間結合との関連におけるｒｎａ配列モチーフ |
| JP2010536907A (ja) * | 2007-08-31 | 2010-12-02 | ニューリミューン セラピューティクス エイジー | 患者にアミロイドーシスおよびタンパク質凝集性障害における特異的免疫応答をもたらす方法 |
| WO2009105641A2 (en) | 2008-02-20 | 2009-08-27 | New York University | Preventing and treating amyloid-beta deposition by stimulation of innate immunity |
| WO2013012875A2 (en) | 2011-07-18 | 2013-01-24 | Mount Sinai School Of Medicine | Bacterial rnas as vaccine adjuvants |
| US10434064B2 (en) | 2014-06-04 | 2019-10-08 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| EP3220895B1 (en) | 2014-11-21 | 2022-08-31 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| MX2020006243A (es) | 2017-12-15 | 2020-09-03 | Bayer Animal Health Gmbh | Oligonucleotidos inmunoestimulantes. |
| WO2024030844A1 (en) * | 2022-08-01 | 2024-02-08 | University Of Mississippi | Choline carboxylic acid based ionic liquids as antimicrobial agents |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5817321A (en) * | 1992-10-08 | 1998-10-06 | Supratek Pharma, Inc. | Biological agent compositions |
| IL112920A (en) * | 1994-03-07 | 2003-04-10 | Dow Chemical Co | Composition comprising a dendritic polymer complexed with at least one unit of biological response modifier and a process for the preparation thereof |
| ID29546A (id) * | 1999-02-15 | 2001-09-06 | Nippon Shinyaku Co Ltd | Polinukleotida dengan rantai yang diperpendek dan metode pembuatannya |
| RU2288921C2 (ru) * | 2000-12-19 | 2006-12-10 | Калифорниа Инститьют оф Текнолоджи | Композиции, содержащие комплексы включения |
| RU2289410C2 (ru) * | 2001-04-04 | 2006-12-20 | Корикса Корпорейшн | Профилактика и лечение инфекционных и других заболеваний с помощью соединений, основанных на моно- и дисахаридах |
| RU2185818C1 (ru) * | 2001-07-10 | 2002-07-27 | НИИ "Молекулярной медицины" Московской медицинской академии им. И.М. Сеченова | Композиция для лечения легочных инфекций |
| IL160157A0 (en) * | 2001-08-17 | 2004-07-25 | Coley Pharm Group Inc | Combination motif immune stimulation oligonucleotides with improved activity |
| EP1499187B1 (en) * | 2002-04-04 | 2015-06-17 | Zoetis Belgium S.A. | Immunostimulatory g,u-containing oligoribonucleotides |
| CN1302948C (zh) | 2002-04-12 | 2007-03-07 | 爱信艾达株式会社 | 车载装置用电源管理系统 |
| DE10229872A1 (de) * | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
| US7956043B2 (en) * | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
| AU2004259204B2 (en) * | 2003-07-15 | 2010-08-19 | Idera Pharmaceuticals, Inc. | Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
| US20050239733A1 (en) * | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
| CA2555390C (en) * | 2004-02-19 | 2014-08-05 | Coley Pharmaceutical Group, Inc. | Immunostimulatory viral rna oligonucleotides |
| MY159370A (en) * | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
| US8076068B2 (en) * | 2005-09-14 | 2011-12-13 | Gunther Hartmann | Method for determining immunostimulatory activity of RNA oligonucleotides |
| ES2536103T3 (es) * | 2005-11-25 | 2015-05-20 | Zoetis Belgium S.A. | Oligorribonucleótidos inmunoestimuladores |
| JP4847609B2 (ja) * | 2007-08-13 | 2011-12-28 | コーリー ファーマシューティカル ゲーエムベーハー | 特異的な免疫修飾プロフィールを誘発する規定されたヌクレオチド間結合との関連におけるｒｎａ配列モチーフ |
-
2008
- 2008-08-08 JP JP2010520640A patent/JP4847609B2/ja active Active
- 2008-08-08 BR BRPI0814260A patent/BRPI0814260B8/pt active IP Right Grant
- 2008-08-08 WO PCT/IB2008/002104 patent/WO2009022216A2/en not_active Ceased
- 2008-08-08 CA CA2696630A patent/CA2696630C/en active Active
- 2008-08-08 ES ES08789054T patent/ES2703876T3/es active Active
- 2008-08-08 NZ NZ582972A patent/NZ582972A/en not_active IP Right Cessation
- 2008-08-08 EP EP08789054.7A patent/EP2179039B1/en active Active
- 2008-08-08 US US12/670,697 patent/US8128944B2/en active Active
- 2008-08-08 SI SI200832023T patent/SI2179039T1/sl unknown
- 2008-08-08 KR KR1020107005451A patent/KR20100045508A/ko not_active Ceased
- 2008-08-08 RU RU2010104618/10A patent/RU2435851C2/ru not_active IP Right Cessation
- 2008-08-08 MX MX2010001014A patent/MX2010001014A/es active IP Right Grant
- 2008-08-08 CN CN2008801113989A patent/CN101821392B/zh active Active
- 2008-08-08 TR TR2018/20474T patent/TR201820474T4/tr unknown
- 2008-08-08 PL PL08789054T patent/PL2179039T3/pl unknown
- 2008-08-08 PT PT08789054T patent/PT2179039T/pt unknown
- 2008-08-08 AU AU2008288241A patent/AU2008288241B2/en active Active
- 2008-08-08 DK DK08789054.7T patent/DK2179039T3/en active
- 2008-08-12 CL CL2008002371A patent/CL2008002371A1/es unknown
- 2008-08-12 TW TW097130681A patent/TW200916106A/zh unknown
- 2008-08-13 AR ARP080103532A patent/AR067928A1/es not_active Application Discontinuation
-
2010
- 2010-02-15 CO CO10016821A patent/CO6260153A2/es not_active Application Discontinuation
-
2012
- 2012-01-30 US US13/360,894 patent/US8227447B2/en active Active
- 2012-06-12 US US13/494,216 patent/US8466124B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010536739A5 (enExample) | ||
| JP5473336B2 (ja) | オリゴヌクレオチドの処方に関する組成物および方法 | |
| EP1737879B1 (en) | Aptamer-mediated intracellular delivery of therapeutic oligonucleotides | |
| WO2006116458B1 (en) | Modified oligoribonucleotide analogs with enhances immunostimulatory activity | |
| RU2010104618A (ru) | Мотивы последовательности рнк в контексте определенных межнуклеотидных связей, индуцирующие специфические имунномодулирующие профили | |
| ES2544958T3 (es) | Análogos de oligonucleótidos CpG que contienen análogos de T hidrófobos con actividad inmunoestimuladora potenciada | |
| ES2486298T3 (es) | Análogos de oligonucleótidos inmunoestimuladores que contienen azúcares modificados | |
| JP2007500018A5 (enExample) | ||
| JP2024518546A (ja) | 修飾されたｍＲＮＡ、修飾された非コードＲＮＡ、およびその使用 | |
| JP2008531018A5 (enExample) | ||
| JP2008523094A5 (enExample) | ||
| JP2017002079A (ja) | センス鎖中の一般塩基またはミスマッチを使用したｓｉＲＮＡサイレンシング活性の亢進 | |
| EP2247308A1 (en) | Adjuvant compositions comprising poly-ic and a cationic polymer | |
| JP2012510297A5 (enExample) | ||
| EP3892727A1 (en) | Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna | |
| WO2008106803A1 (en) | Double-stranded locked nucleic acid compositions | |
| JP2011528910A5 (enExample) | ||
| WO2011005942A2 (en) | Oligonucleotide-based compounds as inhibitors of toll-like receptors | |
| ES2544484T3 (es) | Análogos de oligonucleótidos modificados con fosfato con actividad inmunoestimulante | |
| JP2011250796A5 (enExample) | ||
| KR20110017881A (ko) | 감염 및 신생세포 증식 치료용 올리고뉴클레오티드 | |
| US20080214489A1 (en) | Aptamer-mediated intracellular delivery of oligonucleotides | |
| AU2012220299A1 (en) | Oligonucleotide inhibitors with chimeric backbone and 2-amino-2'-deoxyadenosine | |
| CA2944128C (en) | Capped and uncapped rna molecules and block copolymers for intracellular delivery of rna | |
| EP3696270A1 (en) | Regulation of nucleic acid molecule expression |